Welcome to our dedicated page for Ardelyx SEC filings (Ticker: ARDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing packed with pharmacology data can feel like decoding another language, and Ardelyx’s reports are no exception. Each Ardelyx annual report 10-K simplified on Stock Titan lays out pivotal details—cash runway, Phase 3 results for tenapanor, and royalty streams from overseas partners—that investors must grasp before the next catalyst hits. Our platform turns those dense pages into plain-English answers, giving you Ardelyx SEC filings explained simply without hours of scrolling.
Need specific numbers fast? Open any Ardelyx quarterly earnings report 10-Q filing and our AI instantly flags enrollment costs, FDA meeting minutes, and revenue from IBS-C sales. Toggle to Ardelyx insider trading Form 4 transactions or set alerts for Ardelyx Form 4 insider transactions real-time to spot executive stock moves before markets react. Curious about sudden news? The moment management files an Ardelyx 8-K material events explained notice—whether a trial read-out or partnership amendment—you’ll see a concise summary plus contextual ratios that matter.
Researchers, portfolio managers, and retail traders rely on different forms for different insights. The proxy statement section answers questions like “Ardelyx proxy statement executive compensation” by detailing option grants and pay mixes. “Understanding Ardelyx SEC documents with AI” also means seeing drug milestone obligations right beside balance-sheet impacts. From tracking Ardelyx executive stock transactions Form 4 to diving into an Ardelyx earnings report filing analysis, every disclosure updates in real time, complete with expert commentary so you can act on data instead of digging for it.
Ardelyx, Inc. reported senior leadership changes effective December 31, 2025. Elizabeth Grammer resigned as Chief Legal and Administrative Officer, but will continue as General Counsel until a successor is named and then serve as a Senior Advisor for 24 months under a Transition and Separation Agreement. During an initial 12‑month employment period, she will keep her current base salary, remain eligible for an annual target bonus equal to 45% of base salary for 2025, and continue to receive senior non‑executive benefits, followed by a one‑month salary payment if she delivers a general release.
In the second 12 months, her equity will continue to vest, she may receive advisory payments for the first nine months, and Ardelyx will pay COBRA health premiums for her and dependents during the advisory term or until she gains other coverage. Separately, Chief Medical Officer Edward Conner, M.D. will resign for personal reasons, and Chief Patient Officer and former CMO Dr. Laura Williams will act as interim Chief Medical Officer, overseeing clinical development until a permanent replacement is hired.
Ardelyx, Inc. (ARDX) insider activity: Chief Legal and Administrative Officer Elizabeth Grammer reported a Form 4 transaction dated 11/21/2025. She sold 5,995 shares of Ardelyx common stock at a price of $5.5369 per share. The filing explains that the sale was an automatic sell-to-cover triggered by the vesting of restricted stock units, and the shares were sold solely to cover applicable withholding taxes.
After this transaction, she beneficially owns 299,895 shares of Ardelyx common stock directly.
Ardelyx, Inc. (ARDX) reported an insider stock sale by its president and CEO, who is also a director. On 11/21/2025, the executive sold 46,887 shares of common stock at $5.5369 per share. According to the filing, this sale was made under an automatic sell-to-cover feature tied to restricted stock unit (RSU) awards and was done solely to cover withholding taxes due at vesting.
After this transaction, the executive beneficially owns 1,455,363 shares of Ardelyx common stock directly. In addition, 24,364 shares are held in a living trust and 1,000 shares are held in trusts for the executive’s children, both reported as indirect ownership.
Ardelyx, Inc. (ARDX) reported an insider equity transaction by its Chief Business Officer, Mike Kelliher. On 11/21/2025, he sold 5,560 shares of common stock at a price of $5.5369 per share. The company states these shares were sold automatically upon the vesting of restricted stock units to cover applicable withholding taxes, rather than as a discretionary sale.
Following this transaction, Kelliher directly beneficially owns 271,181 shares of Ardelyx common stock. The filing is a Form 4 submitted for one reporting person and reflects a routine tax-related sale connected to equity compensation.
Ardelyx, Inc. (ARDX) reported an insider share sale by its Chief Patient Officer, Laura A. Williams. On 11/21/2025, Williams sold 6,426 shares of Ardelyx common stock at a price of $5.5369 per share. The filing explains that this was a sell-to-cover transaction imposed by the terms of the original restricted stock unit ("RSU") awards and that the shares were sold solely to cover applicable withholding taxes when the RSUs vested.
Following this tax-related sale, Williams beneficially owned 359,896 shares of Ardelyx common stock, held in direct ownership. The transaction was reported on a Form 4 filed for a single reporting person.
Ardelyx, Inc. (ARDX)11/21/2025, the officer sold 5,814 shares of Ardelyx common stock at a price of $5.5369 per share. According to the explanation, the sale was an automatic sell-to-cover triggered by the vesting of restricted stock units, with shares sold solely to cover withholding taxes. Following this transaction, the officer directly beneficially owns 295,684 shares of Ardelyx common stock.
Ardelyx, Inc. (ARDX) reported an insider equity transaction by Senior Vice President of Finance Joseph J. Reilly. On 11/21/2025, he sold 11,086 shares of common stock at an average price of $5.5369 per share. Following this transaction, he beneficially owned 108,914 shares directly.
The sale was executed pursuant to an automatic sell-to-cover feature tied to previously granted restricted stock units. When the RSUs vested, a portion of the resulting shares was automatically sold to cover applicable withholding taxes, rather than as a discretionary sale of shares.
Ardelyx (ARDX) — Initial ownership filing. CFO Susan Hohenleitner reported 146,896 RSUs, each deliverable as one share of common stock upon vesting. She also holds a stock option for 578,104 shares at an exercise price of $5.01, expiring 10/13/2035. Twenty five percent of the option vests on 10/13/2026, with the remainder vesting in 36 equal monthly installments, subject to continued service.
Ardelyx, Inc. filed a Form S-8 registering 10,000,000 shares of common stock for issuance under its Amended and Restated 2014 Equity Incentive Award Plan, resulting from an increase approved by stockholders on June 18, 2025.
The registration becomes effective upon filing, with sales to occur as awards under the plan are exercised and/or vest. This filing also references and builds on prior S-8 registrations for the 2014 Plan and the ESPP. Standard indemnification, incorporation-by-reference, and exhibit items are included.
Ardelyx reported Q3 results with total revenues of $110,329 thousand. Product sales, net were $105,515 thousand, led by IBSRELA at $78,158 thousand (up 92% year over year), while XPHOZAH contributed $27,357 thousand and reflected lower demand and price following its inclusion in the ESRD Prospective Payment System.
Operating expenses were $101,679 thousand. Net loss was $969 thousand. The quarter included $4,789 thousand of non-cash royalty revenue from Japan partner Kyowa Kirin, including a commercialization milestone of approximately $3.4 million tied to a ¥500.0 million trigger.
Cash, cash equivalents and short-term investments were $242,705 thousand as of September 30, 2025. Long-term debt was $202,138 thousand after drawing a $50,000 thousand Term E Loan on June 30, 2025, with options for an additional $100,000 thousand in committed term loans. Shares outstanding were 242,971,838 as of September 30, 2025.
FAQ
What is the current stock price of Ardelyx (ARDX)?
What is the market cap of Ardelyx (ARDX)?
